Established in 2021 by researchers from the Manchester Institute of Biotechnology, Imperagen is a pioneering techbio company, focused on accelerating the process of enzyme engineering. Serving diverse markets, from pharmaceutical manufacturing and life sciences to sustainable fine chemical production and industrial applications, we work hand-in-hand with our customers to de-risk and streamline their product development and fast track their path to market.
Imperagen: Venture Capital Funding History
Imperagen
Imperagen
- Life Sciences
- Manchester, United Kingdom
- £5m
- imperagen.com
- Update Information
More venture news
- 13 Nov 2026

Oyster TherapeuticsOyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
Series ALife Sciences - 10 Nov 2026

Neobe TherapeuticsNeobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
SeedLife Sciences - 9 Nov 2026

PhaSER BiomedicalPhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
GrantLife Sciences
